ATE121623T1 - Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie. - Google Patents

Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie.

Info

Publication number
ATE121623T1
ATE121623T1 AT91114290T AT91114290T ATE121623T1 AT E121623 T1 ATE121623 T1 AT E121623T1 AT 91114290 T AT91114290 T AT 91114290T AT 91114290 T AT91114290 T AT 91114290T AT E121623 T1 ATE121623 T1 AT E121623T1
Authority
AT
Austria
Prior art keywords
arrhythmia
quinazolinees
prevention
treatment
production
Prior art date
Application number
AT91114290T
Other languages
English (en)
Inventor
Toshiji Igarashi
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE121623T1 publication Critical patent/ATE121623T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT91114290T 1985-07-16 1986-07-11 Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie. ATE121623T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60155096A JPH0647540B2 (ja) 1985-07-16 1985-07-16 虚血性心疾患・不整脈治療・予防剤

Publications (1)

Publication Number Publication Date
ATE121623T1 true ATE121623T1 (de) 1995-05-15

Family

ID=15598537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91114290T ATE121623T1 (de) 1985-07-16 1986-07-11 Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie.

Country Status (5)

Country Link
US (1) US4707477A (de)
EP (2) EP0461681B1 (de)
JP (1) JPH0647540B2 (de)
AT (1) ATE121623T1 (de)
DE (1) DE3650311T2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
EP1275403A1 (de) * 2001-07-10 2003-01-15 Lin I. Shan Zusätze für eine Damenbinde und Verfahren zum Hinzufügen derselben
KR100469085B1 (ko) * 2002-05-23 2005-01-29 (주) 비엔씨바이오팜 3,4,5-트리플루오로피리딘 유도체, 그의 제조방법 및 이를포함하는 항바이러스용 약학적 조성물
AU2007245037A1 (en) * 2006-03-29 2007-11-08 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4966691A (de) * 1972-10-30 1974-06-27
JPS5182285A (en) * 1974-04-16 1976-07-19 Eisai Co Ltd Kinatsuorinkeikagobutsu no goseihoho
JPS537436B2 (de) * 1974-04-16 1978-03-17
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
US4189484A (en) * 1977-11-08 1980-02-19 Mitsubishi Yuka Pharmaceutical Co., Ltd. Antihypertensive quinazoline derivatives
US4607034A (en) * 1979-10-29 1986-08-19 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinazoline derivatives and pharmaceutical composition thereof
GB2068961B (en) * 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
JPS57116052A (en) * 1981-01-13 1982-07-19 Sankyo Co Ltd Quinazoline derivative and its preparation
GR75878B (de) * 1981-03-05 1984-08-02 Pfizer
CH651027A5 (de) * 1982-11-12 1985-08-30 Sandoz Ag Heterocyclische verbindungen, ihre herstellung und verwendung.
DE3336409A1 (de) * 1983-10-06 1985-04-18 Ludwig Heumann & Co GmbH, 8500 Nürnberg Chinazolinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
EP0461681B1 (de) 1995-04-26
JPH0647540B2 (ja) 1994-06-22
EP0209089A3 (de) 1990-01-31
JPS6216417A (ja) 1987-01-24
EP0461681A2 (de) 1991-12-18
EP0461681A3 (en) 1992-02-05
DE3650311T2 (de) 1995-10-12
DE3650311D1 (de) 1995-06-01
US4707477A (en) 1987-11-17
EP0209089A2 (de) 1987-01-21

Similar Documents

Publication Publication Date Title
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69201948T2 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
DE3888340T2 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
DE69327328T2 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
DE3785740T2 (de) Verwendung von Carboxamid-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der Hyperlipämie.
DE69104314D1 (de) Verwendung von 1-[3-(Dimethylamino)propyl]-1-phenylphthalenen zur Behandlung zerebrovaskulärer Störungen.
DE3873578D1 (de) Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE98488T1 (de) Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit beta-blockern oder bradycardica.
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE68919378T2 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
ATE135573T1 (de) Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten
ATE121623T1 (de) Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie.
ATE63541T1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
ES2016305B3 (es) Compuestos de piperazina, procedimiento para prepararlos y composicion farmaceutica y su uso.
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
NO159271C (no) Analogifremgangsmaate for fremstiling av terapeutisk aktive substituerte isokinolinderivater.
DE3884878T2 (de) Uricosuretische Zusammensetzung.
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ATE132748T1 (de) Verwendung eines dihydropyridins zur verbesserung der blutzirkulation des inneren ohres

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee